Zimmer Biomet Holdings Inc (NYSE:ZBH) – Analysts at Jefferies Financial Group lowered their FY2019 earnings per share estimates for shares of Zimmer Biomet in a note issued to investors on Tuesday, November 5th. Jefferies Financial Group analyst R. Denhoy now forecasts that the medical equipment provider will post earnings of $7.84 per share for the year, down from their prior forecast of $7.85. Jefferies Financial Group has a “Buy” rating and a $167.00 price objective on the stock. Jefferies Financial Group also issued estimates for Zimmer Biomet’s Q4 2019 earnings at $2.27 EPS, Q1 2020 earnings at $1.94 EPS, Q2 2020 earnings at $2.03 EPS, Q3 2020 earnings at $1.91 EPS, Q4 2020 earnings at $2.43 EPS, FY2020 earnings at $8.30 EPS and FY2021 earnings at $8.82 EPS.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, November 5th. The medical equipment provider reported $1.77 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.75 by $0.02. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a positive return on equity of 13.89% and a negative net margin of 1.14%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.63 EPS.

ZBH has been the subject of several other research reports. Leerink Swann boosted their price objective on Zimmer Biomet from $155.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday. They noted that the move was a valuation call. BTIG Research raised Zimmer Biomet from a “neutral” rating to a “buy” rating and set a $158.00 price objective for the company in a report on Monday, October 7th. Oppenheimer boosted their price objective on Zimmer Biomet from $135.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, July 29th. ValuEngine lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. Finally, Cowen set a $140.00 price objective on Zimmer Biomet and gave the stock a “buy” rating in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $147.95.

Shares of NYSE ZBH opened at $144.00 on Friday. Zimmer Biomet has a 12 month low of $96.99 and a 12 month high of $144.96. The company has a current ratio of 1.19, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $28.81 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 2.66 and a beta of 1.14. The business has a 50-day moving average of $137.06 and a 200-day moving average of $128.64.

Hedge funds have recently made changes to their positions in the business. Allworth Financial LP lifted its position in Zimmer Biomet by 65.0% in the third quarter. Allworth Financial LP now owns 203 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 80 shares during the last quarter. Personal Wealth Partners bought a new stake in Zimmer Biomet in the second quarter valued at approximately $26,000. TRUE Private Wealth Advisors bought a new stake in Zimmer Biomet in the second quarter valued at approximately $26,000. Coastal Investment Advisors Inc. lifted its position in Zimmer Biomet by 271.0% in the second quarter. Coastal Investment Advisors Inc. now owns 256 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 187 shares during the last quarter. Finally, Bridger Capital Management LLC bought a new stake in Zimmer Biomet in the third quarter valued at approximately $39,000. Hedge funds and other institutional investors own 87.72% of the company’s stock.

In other Zimmer Biomet news, insider Didier Deltort sold 360 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $139.25, for a total value of $50,130.00. Following the completion of the sale, the insider now owns 1,194 shares in the company, valued at $166,264.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Chad F. Phipps sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $138.28, for a total value of $967,960.00. Following the completion of the sale, the vice president now owns 37,722 shares of the company’s stock, valued at approximately $5,216,198.16. The disclosure for this sale can be found here. Insiders sold a total of 40,244 shares of company stock valued at $5,621,885 in the last 90 days. 0.72% of the stock is currently owned by corporate insiders.

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were given a $0.24 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.67%. Zimmer Biomet’s payout ratio is 12.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: Hedge Funds – How They Work For Investors

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.